article thumbnail

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Each exclusion list now contains about 600 products. Click here to see the original post and comments from January 2023.

Insulin 97
article thumbnail

The Big Three PBMs’ 2023 Formulary Exclusions: Observations on Insulin, Humira, and Biosimilars

Drug Channels

For 2023, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)—have again increased the number of drugs they exclude from their standard formularies. Each exclusion list now contains about 600 products.

Insulin 94
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions

Drug Channels

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Each exclusion list contains 400 to 500 products.

Insulin 96
article thumbnail

Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions (rerun)

Drug Channels

For 2022, the three largest pharmacy benefit managers (PBMs)—Caremark (CVS Health), Express Scripts (Cigna), and OptumRx (United Health Group)— increased the number of drugs they excluded from their standard formularies. Each exclusion list contains 400 to 500 products.

Insulin 86
article thumbnail

FDA Warns About Compounded Versions of Ozempic and Wegovy

XTalks

Ozempic and Wegovy, which contain the active ingredient semaglutide, were approved by the US Food and Drug Administration (FDA). GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. mg and 2.4 mg doses of Wegovy.

article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

One of these markets is the insulin market. Up until now, the insulin market has experienced little competition and, as a result, prices have soared over the years. Currently, more than seven million patients rely on insulin, and that number is growing each year. But, that will soon be changing, due to biosimilars.

Marketing 108
article thumbnail

LillyDirect: New Home Delivery Service for Eli Lilly’s Diabetes, Weight Loss and Migraine Drugs

XTalks

Among its services, Lilly said LillyDirect provides disease management resources that include access to independent healthcare providers, personalized support and direct delivery of select Lilly medications to homes via third-party pharmacy dispensing services.

Drugs 59